Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma

Fig. 2

Sample IHC images of PODXL expression from a patient with adenocarcinoma in the gastroesophageal junction: a pre-neoadjuvant biopsy with moderate cytoplasmic positivity in tumor cells (score 2), b TMA core from post-neoadjuvant resected primary tumor with moderate cytoplasmic positivity in tumor cells (score 2), and c TMA core from post-neoadjuvant resected lymph node metastasis with distinct membranous positivity in ≤ 50% of tumor cells (score 3). Scale bar = 20 µm

Back to article page